Bionano Genomics, Inc.
BNGO Healthcare Medical Instruments & Supplies
Bionano Genomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $28.5 million, down 7.37% from fiscal 2024. In the quarter to June 2026, revenue grew 21.4%, EPS grew 67.8%, free cash flow fell 33.9% and total debt fell 1.91%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow BNGO
Bionano Genomics, Inc. (BNGO) Altman Z-score
Bionano Genomics, Inc.'s Altman Z-score for fiscal 2025 is −14.26, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −14.26 | 2.12 |
| FY2024 | −16.38 | (9.99) |
| FY2023 | −6.39 | (8.32) |
| FY2022 | 1.93 | (9.88) |
| FY2021 | 11.81 | 8.74 |
| FY2020 | 3.07 | 9.82 |
| FY2019 | −6.75 | (2.82) |
| FY2018 | −3.93 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.31 | — | 0.37 | |
| Retained earnings / total assets | (9.78) | — | −13.69 | |
| EBIT / total assets | (0.45) | — | −1.50 | |
| Market value of equity / total liabilities | 0.29 | — | 0.17 | |
| Sales / total assets | 0.39 | — | 0.39 | |
| Altman Z-score | Distress zone | −14.26 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −31.33 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| NXGL NexGel, Inc. compare | 24.6× |
| RVP Retractable Technologies, Inc. compare | 0.6× |
| CUPR Cuprina Holdings (Cayman) Limited compare | −1.0× |
| LUCY Innovative Eyewear, Inc. compare | −3.7× |
| HBIO Harvard Bioscience, Inc. compare | −4.0× |
| FEMY Femasys Inc. compare | −10.9× |
| BNGO Bionano Genomics, Inc. | −14.3× |
| MLSS Milestone Scientific, Inc. compare | −22.1× |
| RGNT Regentis Biomaterials Ltd. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets